AtriCure (NASDAQ:ATRC) Director Sven Wehrwein Sells 25,000 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the sale, the director owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AtriCure Price Performance

ATRC stock opened at $40.15 on Friday. The firm has a 50 day simple moving average of $30.91 and a two-hundred day simple moving average of $31.29. The stock has a market cap of $2.04 billion, a PE ratio of 191.20 and a beta of 1.24. AtriCure, Inc. has a one year low of $25.36 and a one year high of $43.18. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter last year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts predict that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: UBS lowered its price target from $55 to $50 but maintained a Buy rating, implying substantial upside from recent trading levels. The revised target remains supportive of the long-term outlook for AtriCure’s medical-device business. UBS price target report
• Positive Sentiment: AtriCure recently exceeded quarterly expectations, reporting earnings per share of $0.18 versus an analyst estimate of $0.13 and revenue of $153.6 million versus estimates of $151.8 million. Results also improved from a loss in the year-ago period, supporting the company’s growth and profitability narrative. AtriCure earnings report
• Neutral Sentiment: Recent coverage is focused on whether options activity signals an unusually large upcoming move in ATRC. No specific direction is established, but elevated options interest may contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: Investors are also reviewing new share-registration filings. Such filings can provide AtriCure with financing flexibility, although the potential for future share issuance may raise dilution concerns. AtriCure share registration article
• Negative Sentiment: Several insiders sold shares: Director Sven Wehrwein reduced his holdings by about 38%, while executives Justin J. Noznesky and Vinayak Doraiswamy cut their positions by approximately 6% each. The sales, totaling roughly $1.42 million, may weigh on sentiment, particularly after ATRC’s strong recent run.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Canaccord Genuity Group upped their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $48.50.

Hedge Funds Weigh In On AtriCure

Hedge funds and other institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC raised its position in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. Scotia Capital Inc. grew its position in shares of AtriCure by 1.2% in the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after buying an additional 457 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after buying an additional 543 shares during the period. Captrust Financial Advisors increased its stake in shares of AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in shares of AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after acquiring an additional 683 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.